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initiation of a new DMARD within 60 days of the discontinuation date of the index
biologic; intermittent use of the index biologic--60 days of treatment gap, ‘step-
down’--discontinuation of one of the DMARD therapies from the initial combo
therapy, ‘step-up’--adding a new DMARD for 28 consecutive days. Numbers are
reported in pairs with ETN first and ADA second. RESULTS: Over the 12-month
study period, majority of PsA patients newly initiated ETN/ADA (N2037/2217) had
1 therapy change (65.3%/69.1% with a median time to change: 113/112 days). Among
patients initiated on mono ETN/ADA (N1410/1496), 40.7%/33.5% patients remained
on the index mono therapy, 12.1%/11.6% patients discontinued the treatment, 18.2%/
14.7% patients had intermittent treatment, 7.0%/11.4% switched to another mono
therapy, and 21.9%/29.1% step-up to combo therapy. Among patients initiated on ETN/
ADA in combination with an oral DMARD, 21.4%/26.8% remained on the original
combo therapy, 77.5%/72.7% ‘stepped down’ to a mono therapy, and very few patients
discontinued therapy (0.5%/0.1%) or adopting intermittent biologic therapy
(0.6%/0.3%). CONCLUSIONS: This study suggests that most of the PsA patients
newly initiated on ETN or ADA have a therapy change over the first year.
URINARY/KIDNEY DISORDERS - Clinical Outcomes Studies
PUK1
A SWEDISH PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE
IMPACT IN QUALITY OF LIFE AMONG PREVIOUSLY UNTREATED PATIENTS
RECEIVING THEIR FIRST PRESCRIPTION OF SOLIFENACIN. (SPOQ-STUDY)
Mattiason A1, Persson CA2
1Skane University Hospital, Lund, Sweden, 2Astellas Pharma, Kastrup, Denmark
OBJECTIVES: To evaluate in daily clinical practice possible changes in perceived
quality of life (QoL) in patients treated with solifenacin and also to investigate
whether the treatment had an impact on the use of incontinence pads. METHODS:
This non-interventional study consisted of one visit at the study centres per pa-
tient and two follow-up questionnaires (13-item QoL and 6-item bother scale,
OAB-q SF) after 3 months and 6 months, answered by the patients at home.
RESULTS: A total of 232 patients were included in the study at 35 centers in Swe-
den. Sixty patients participated at baseline only. The age of patients ranged from 25
to 87 years (mean 64 years). One hundred and sixty-seven patients (97.1%) were
women and 5 patients (2.9%) were men. Almost all of the participating investiga-
tors were specialists in gynecology, which explains the large proportion of women
among the patients. Solifenacin significantly improved self-perceived health-re-
lated quality of life, as measured by the 13-item QoL scale of the OAB-q SF, at 3
months vs. baseline (p .0001) and at 6 months vs. baseline (p .0001) and also
when 6 months and 3 months data were compared (p0.007), in anti-muscarinic
naive OAB patients. Solifenacin significantly improved self-perceived health-re-
lated quality of life, as measured by the 6-item bother scale of the OAB-q SF, at 3
months vs. baseline (p .0001) and at 6 months vs. baseline (p .0001). The mean
use of pads significantly decreased from 19 to 12 pads per week. Solifenacin signif-
icantly decreased the use of pads at 3 months vs. baseline (p .0001) and at 6
months vs. baseline (p.0001). CONCLUSIONS: Solifenacin significantly improved
self-perceived health-related quality of life, as measured by both the 13-item QoL
scale and the 6-item bother scale of the OAB-q SF. Solifenacin significantly de-
creased the use of pads per week.
PUK2
ISSUES IN THE SYSTEMATIC REVIEW OF DRUGS FOR RARE DISEASES: A CASE
STUDY OF ECULIZUMAB FOR AHUS
Kaltenthaler E1, Rathbone J2, Tappenden P1, Bessey A3, Cantrell A4
1University of Sheffield, Sheffield, UK, 2University of Sheffield, Sheffield, South Yorkshire, UK,
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OBJECTIVES: Assessing the clinical effectiveness of drugs for rare diseases pres-
ents many challenges for systematic reviewers. Atypical haemolytic uraemic syn-
drome (aHUS) is a rare disease with a worldwide prevalence of between 2.7 and 5.5
per million population. A systematic review was undertaken to assess the clinical
effectiveness of eculizumab for the treatment of aHUS. The aim of this research
was to highlight issues with applying standard systematic review methods to as-
sess clinical effectiveness where the evidence base is not well developed.
METHODS: A systematic review using standard methods was undertaken of ecu-
lizumab for the treatment of aHUS. RESULTS: Standard search methods did not
identify all relevant information and other sources of evidence were used, such as
hand searching and internet searching. Three studies were identified showing
eculizumab to be beneficial in treating aHUS. However serious concerns were iden-
tified with the evidence base in the review. The issues of concern were: lack of a
control group in any of the studies, the use of surrogate outcome measures only,
little information available on comparator treatments, lack of clarity on patient
selection in the trials and no baseline data available for this patient population.
Very little information on eculizumab for aHUS was available in the public domain.
CONCLUSIONS: The issues highlighted here are of concern in the review of other
rare diseases, where information may also be scarce. Guidance is needed on ap-
propriate study designs. There is a need for validated surrogate outcomes and final
patient related outcomes, a need for registries of baseline data, long term follow-up
data and adverse event information to enable the monitoring of the natural course
of the disease. Guidance is need on best practice for the recruitment and selection
of patients for trials of treatments for rare diseases.
PUK3
EVALUATION OF MEDICATION-RELATED PROBLEMS IN HEMODIALYSIS
PATIENTS
Wu CL
Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
OBJECTIVES: Patients under hemodialysis (HD) may have many medication-re-
lated problems (MRPs) due to their medical complexity. The study objective was to
identify MRPs experienced by inpatients under HD upon admission in Wang-Fang
hospital in Taiwan.METHODS: Patients on either regular or irregular hemodialysis
from 24th October to 11th November in 2011 were included in this study. Patients
who did not use any drugs were excluded. Demographic and types of MRPs were
assessed by descriptive statistics. RESULTS: A total of 81 patients were evaluated,
and 67 MRPs were identified. Each patient used 11 drugs on average. Patients using
over 12 drugs were at higher risk of occurring MRPs. Among the 67 MRPs, the most
common type of MRP was drug interaction (50.7%), followed by overdose (37.3%).
Pharmacists intervened 17.91% of the MRPs and also kept monitoring 58.2% of the
MRPs. Physicians accepted 91.67% of the pharmacy interventions. Patients under
regular (n67) or irregular HD (n14) were also compared in our study. Different
types of MRPs were shown between the two groups. Drug interaction occurred
more often in patients on regular HD (n32, 47.8%), while overdose was more
commonly discovered in irregular HD group (n7, 50%).CONCLUSIONS:MRPs exist
commonly in HD patients. The study showed that patients using 12 or more drugs
were at higher risk of occurring MRPs. Patients under regular or irregular HD may
have different patterns of MRPs. Pharmacists should be more careful when evalu-
ating these patients’ medications.
URINARY/KIDNEY DISORDERS - Cost Studies
PUK4
A COST-COMPARISON ANALYSIS OF TREATING OVERACTIVE BLADDER (OAB)
WITH FESOTERODINE, TOLTERODINE OR SOLIFENACIN IN DAILY CLINICAL
PRACTICE IN SPAIN
Sicras-Mainar A1, Rejas J2, Navarro-Artieda R3, Aguado-Jodar A4, Ruiz-Torrejón A5, Kvasz
MG6
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OBJECTIVES: To compare health care resource utilization and costs in OAB adults
receiving fesoterodine, solifenacin or tolterodine in clinical practice in Spain.
METHODS:A retrospective study was designed using primary care electronic med-
ical records from three towns in Spain. Records of patients who initiated OAB
therapy between 2008 and 2010 and with a follow-up of at least 52 weeks were
retained. Patients over 18 of both genders with an OAB diagnosis [ICD-9-CM 596.51]
and a new prescription of fesoterodine, tolterodine or solifenacin were included in
the analyses. All type medical visits (primary care, specialist and emergency room),
absorbents for urinary incontinence, complementary/diagnostic tests and con-
comitant medications related with OAB along with cost of antimuscarinics used
were analyzed (NHS perspective). Comparisons between antimuscarinics were ad-
justed by location, age, sex, time since diagnosis, co-morbidity burden and medi-
cation possession ratio (medication/time), and were compared using univariate
general linear models with bootstrap (1000 re-samples) bias correcting methods to
calculate 95% confidence intervals. RESULTS: A total of 1,971 records (58.3%
women, 70.1 [SD: 10.6] years) were analyzed; 302 treated with fesoterodine, 952
with solifenacin and 717 with tolterodine. Respectively, 17%, 22% and 25% of sub-
jects used absorbents during the study (p0.014). Adjusted mean health care costs
(95% bootstrap CI) were significantly lower with fesoterodine treatment [€1639
(1542; 1725)] compared with solifenacin [€1780 (1699; 1854), p0.022] or tolterodine
[€1893 (1815; 1969), p0.001]. All medical visits costs were also lower with fesotero-
dine €433 (411; 457) than with solifenacin [€533 (515; 552); p0.001] or tolterodine
[€563 (539; 585), p0.001]. Drug costs due to co-morbidities associated with OAB
were also lower with fesoterodine [€216 (180; 258)] compared with solifenacin [€305
(274; 338); p0.002] or tolterodine [€335 (306; 366), p0.001]. CONCLUSIONS: Treat-
ment of OAB with fesoterodine in clinical practice in Spain was a cost-saving ther-
apy from the NHS perspective as compared to solifenacin or tolterodine.
PUK5
EMPLOYMENT RATES AND INDIRECT COSTS IN PATIENTS WITH END-STAGE
RENAL DISEASE: DIFFERENCES BETWEEN MODALITIES OF RENAL
REPLACEMENT THERAPY
Julián JC1, Cuervo J2, Rebollo P2, Castejón N2, Callejo D2
1ALCER Renal Foundation, Madrid, Spain, 2LA-SER (BAP LA-SER Outcomes), Oviedo, Asturias, Spain
OBJECTIVES: The present study aims to compare the work status and the indirect
costs associated to morbidity in end-stage renal disease patients undergoing one of
the following alternatives of renal replacement therapy (RRT): Hemodialysis in a
specialized center (HD), automated peritoneal dialysis (APD), continuous ambula-
tory peritoneal dialysis (CAPD), and renal transplant (TX). METHODS: An analysis
on indirect costs from morbidity on RRT was implemented, following the Human
Capital Theory. An epidemiological, multicenter, cross-sectional study was con-
ducted. A total of 243 patients in working age were included (32 CAPD, 46 APD, 83
HD and 82 TX). The potentially productive years of life lost (PPYL), the costs of lost
labor productivity (LLPc) for the year 2009 and the total cost of PPYL (PPYLtc) until
age of retirement were estimated. All the estimations were adjusted by age, sex and
different activity rates (obtained from the Spanish National Institute of Statistics).
Besides, discount rates of 0%, 3% and 6% were also considered. Chi2 tests and
Kruskal-Wallis or Mann-Whitney U (Bonferroni correction) statistics were used to
compare socio-demographic and clinical variables. Due to its skewed distribution,
non-parametric analysis (a bootstrap confidence intervals of differences in costs
calculated following the simple bias-corrected percentile method -1,000 bootstrap
estimates-) was computed to highlight differences in costs. RESULTS: No signifi-
cant differences were found in age or sex between groups (p0.05). The PPYL were:
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HD 12.58 years-95%CI:10.42-14.73-; TX 10.05-95%CI:7.45-12.65-; APD 6.09-95%CI:
3.43-8.74-; CAPD 10.69-95%CI: 6.14-15.23-.The LLPc-2009- in HD (6,547€-95%CI:
5,727€-7,366€-) was significantly higher (p0.001) than TX (5,079€-95%CI:4,127€-
6,030€-) or APD (4,359€-95%CI:3,064€-5,655€-) but not CAPD (5,785€-95%CI:4,302€-
7,269€-). PPYLtc was higher in HD than in TX, APD or CAPD in all the provided
scenarios. CONCLUSIONS: APD is the alternative with the lowest impact on indi-
rect costs due to morbidity. Besides, TX recipients also have higher rates of em-
ployment than HD and require less disability benefits.
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THE ECONOMIC BURDEN OF POST-TRANSPLANT EVENTS IN RENAL
TRANSPLANT PATIENTS IN GERMANY (THE PORTRAIT STUDY)
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OBJECTIVES: Little information is available on the prevalence of post-transplant
events and resource utilization associated with such events in renal transplant (RT)
patients in clinical practice in Germany. The PORTRAIT study aims to describe the
health care resources used and to estimate the cost of managing post-transplant
patients using observational data from transplant databases and physician ques-
tionnaires from transplant centers across Europe. Aggregated study results have
been previously communicated; this abstract describes the results from two Ger-
man centers. METHODS: A retrospective observational study was undertaken in
which resource usage over three years was employed to derive costs from a third
party perspective, with results stratified by glomerular filtration rate (GFR) status at
one-year post transplant. Descriptive statistics were used to detail medical re-
source use and its costs. Post-transplant events considered were: hospitals stays,
delayed graft function, outpatient appointments, laboratory tests, anaemia, hyper-
tension, dyslipidaemia and infections. Immunosuppressant drug costs were not
considered in this analysis. RESULTS: Four hundred and fourteen patients from
both sites were included in the analysis. The total three-year cost of post-trans-
plant care by GFR at one year varies from a minimum of €20,632 per patient to a
maximum of €43,163 per patient. The average three-year costs decrease as a result
of improved graft functioning status (increased GFR) at one year. The average
three-year costs for a patient with a GFR45mL/ min/1.73 m2 at one year are 40%
lower than those patients with a GFR30 mL/ min/1.73 m2. CONCLUSIONS: In line
with the multinational results, the German results provide evidence that post-
transplant resource usage in a real-life treatment setting increases as post-trans-
plant renal function worsens. Therefore management strategies that promote re-
nal function post transplant are likely to provide important resource savings to the
health care system.
PUK7
COST OF ILLNESS OF OVERACTIVE BLADDER SYNDROME IN HUNGARY
Brodszky V1, Gulácsi L1, Majoros A2, Piróth C3, Böszörményi-Nagy G4, Baji P5, V. Hevér
N1, Balogh O1, Péntek M1
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OBJECTIVES: Overactive bladder syndrome (OAB) is a urological condition defined
by a set of symptoms including urgency, with or without urge incontinence, usually
with frequency and nocturia. Our aim was to assess the productivity and costs of
women with OAB in Hungary.METHODS: Cross-sectional survey was performed in
5 urology/gynecology outpatient centres. Demographic and clinical characteristics
were recorded. Medication, health and informal care utilisation were surveyed for
the past 12 months. The Work Productivity and Activity Impairment questionnaire
(WPAI) was used to assess productivity. Cost calculation was performed from the
societal perspective and human capital approach was used. RESULTS: Sixty-six
women with mean age of 56.9 (SD12.4) years participated in the study, 3 (5%)
singles, 38 (58%) married, 14 (21%) divorced and 11 (17%) widows. Forty-six (70%)
were in menopause and 45 (69%) were overweighted. Patients have had symptoms
for 6.6 (SD6.2) years in average, 62 (94%) had incontinence of whom 41 (66%)
experienced incontinence episodes daily and 30 (48%) used incontinence pads.
Twenty-six patients (39%) were taking medication for OAB and 22 (33%) had anti-
biotic treatment due to urinary symptoms in the past year. Patients had diverse
diagnostic procedures (e.g. ultrasound: 98%, cystometry 49%, uroflow 64%, cystos-
copy 20%), 10 (15%) were admitted to hospital due to urinary problem. Twenty-
three (35%) patients were working and 2 of them were on sick-leave in the past
year. WPAI results of active workers were: abstenteeism 0.04%, presenteeism
44.6%, impaired activity 48.2%, this latest was 50.7% for non-workers. Total costs
were €340/patient/year (conversion €1275.4 HUF), rate of direct medical, direct
non-medical and indirect cost was 92.6%, 6.8% and 0.6%, respectively.
CONCLUSIONS: Our study is the first to offer data on productivity and costs of
patients with OAB in Hungary. Results suggest that presenteesm is a major prob-
lem and direct medical costs (diagnostics, drugs) are dominant.
PUK8
4-YEAR INCIDENCE AND COSTS OF HOSPITALIZED COMPLICATIONS WITHIN
KIDNEY TRANSPLANT PATIENTS IN FRANCE
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OBJECTIVES: Complications are common following kidney transplantation. The
French Hospital National Database (PMSI) allows patients follow-up through their
hospitalization reports. This study assessed 4-year incidences of complications
after kidney transplantation and estimated their economic impact, in particular
renal complications.METHODS: From the years 2006-2010, hospitalization data for
all patients with kidney transplantation in year 2006 were extracted. Patients’ hos-
pital stays were followed during a period of 4 years. Major hospitalizations of in-
terests were pooled in renal, cardiovascular and infectious complications. Renal
complications were detailed in graft loss, acute renal insufficiency (ARI), acute
rejection (AR), recurrence of initial nephropathy (RIN), chirurgical complication
and, others. Incremental costs were estimated by subtracting transplantation-year
mean cost of patients without any renal complications to the one of those with
renal complications the same year. Mean annual costs of patients with graft loss
were assessed separately for each year. Costs were calculated according to the 2010
National Hospital Tariff and National Scale. RESULTS: A total of 2392 patients with
kidney transplantation in 2006 were identified. A total of 61.5% were males and
mean age was 45.0(14.9) years old. 4-year cumulative incidences of renal, cardio-
vascular and infectious complications were 54.8% (n1,311), 20.8% (n498) and
19.8% (n474). Incidences of ARI, AR, RNI, chirurgical complication and, others
renal complications were 24.5%, 21.1%, 4.1%, 3.1% and 22.4%, respectively. Com-
pared to other patients without any renal complication (First-year mean costs:
€25,170; Q1:€17,341–Q3:€27,649), the corresponding incremental costs for renal
complications were €7,046, €10,376, €10,238, €7,874 and, €5,668. During the 4-year
period, graft loss occurred in 4.4% patients. Annual mean costs of graft loss for the
first, second, third and fourth years were €32,159 (Q1:€11 723–Q3:€41,890) (n105),
€19,085 (n64), €25,269 (n52) and, €20,780 (n41), respectively. CONCLUSIONS:
After transplantation, short-term renal complications are frequent and expensive.
Intensive interventions on renal preservation and graft loss prevention are needed.
PUK9
DIRECT AND INDIRECT COST OF URGE URINARY INCONTINENCE WITH AND
WITHOUT PHARMACOTHERAPY
Goren A1, Zou KH2, Gupta S3, Chen CI2
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OBJECTIVES: To evaluate the impact of treating urge urinary incontinence (UUI) on
health care resource utilization, productivity, activity impairment, and associated
costs. METHODS: The study used data (N75,000) from the 2011 National Health
and Wellness Survey, a self-administered, Internet-based questionnaire of a na-
tionwide sample of adults (age 18). Respondents with UUI or MUI were identified
via 3 Incontinence Questions. Respondents with stress urinary incontinence only,
prostate cancer, or (medication for) benign prostatic hyperplasia, were excluded.
UUI/MUI respondents were categorized as using prescription medication (Rx users)
for overactive bladder (OAB) and non-Rx users (who never used Rx and whose
condition reportedly interfered with life activities or was difficult to manage). Out-
come measures included health care utilization (type/number of resources used
within the past 6 months) and Work Productivity and Activity Impairment ques-
tionnaire-based scores. Direct and indirect costs were estimated using 2010 labor
and 2008 medical expenditure data sources. Generalized linear models predicted
resource use and productivity as a function of treatment status, adjusting for co-
variates (e.g., sociodemographics, BMI, OAB severity, UUI vs. MUI, and comorbid
status) that may also predict impairment. RESULTS:Among 1,190 UUI/MUI respon-
dents, 481 were defined as Rx and 709 as non-Rx users. Rx (vs. non-Rx) users were
more likely to be female (80.7% vs. 70.0%), older (mean62.7 vs. 53.1), non-Hispanic
White (82.3% vs. 69.7%), college educated, health-insured (94.6% vs. 81.7%), unem-
ployed/retired (72.6% vs. 57.7%), and reporting more moderate-to-severe OAB
(70.9% vs. 52.6%; all p0.05). Adjusting for covariates, Rx (vs. non-Rx) users had
lower activity impairment (41.1% vs. 46.8%), more provider visits (7.42 vs. 5.60) and
costs ($18,175 vs. $13,679), and higher total direct costs ($27,291 vs. $21,493), all
p0.01. CONCLUSIONS: UUI patients using, vs. never using, prescription medica-
tion reported lower activity impairment but higher direct costs. The findings may
inform the degree to which UUI pharmacotherapy affects health outcomes.
PUK10
COMPARATIVE COST-ANALYSIS OF SIX ANTICHOLINERGICS FOR THE
TREATMENT OF OVERACTIVE BLADDER AND INCONTINENCE IN GERMANY
Mayrhofer T1, Grabe K2, Felder S3
1University of Duisburg-Essen, Essen, Germany, 2Astellas Pharma GmbH, Munich, Germany,
3University of Basel, Basel, Switzerland
OBJECTIVES: Comparing the costs of Solifenacin, Oxybutynin, Trospium chloride,
Tolterodine, Propiverine, and Darifenacine for the treatment of overactive bladder
(OAB) and incontinence in Germany. DATA AND METHODS: The cost-study is
based on a unique sickness fund dataset of 2.9 million insured persons which
included pharmaceutical, outpatient, inpatient, medical aids as well as remedies
data in 2009. 25,896 persons received anticholinergics and were classified as OAB
patients. 4,152 of these patients also suffered from incontinence. Multiple linear
regression models were performed to control for age and gender effects. Further-
more, a general approach (all costs were included) as well as a specific approach
(only costs associated with OAB were considered) were used. RESULTS: OAB pa-
tients caused additional costs of €2,492 using the general and €782 using the spe-
cific approach compared to Non-OAB patients. Patients treated with Propiverine
(€1,854) had the lowest additional costs under the general approach and patients
treated with Darifenacine (€3,230) the highest. In the specific approach, patients
treated with Propiverine (€691) had the lowest additional costs and patients treated
with Tolterodine (€1,124) the highest. In the special case of incontinence, patients
treated with Solifenacin have shown, by far, the lowest additional costs using
either approach (€3,216; €1,320). These results are mainly driven by the lower costs
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